Navigation Links
Tufts Medical Center researchers receive $10 million NIH grant to test blood clot prevention drug
Date:7/3/2012

Boston, Mass. (July 3, 2012) Tufts Medical Center researchers are developing a first-of-its-kind drug to prevent deadly blood clots in heart disease patients, without the risk of serious bleeding associated with current medications. The National Heart, Lung, and Blood Institute of the National Institutes of Health has just awarded the team led by Athan Kuliopulos, MD, PhD, a $10 million grant to start testing a drug based on this novel technology.

"If our study works, it's potentially game-changing and could become part of the standard of care for patients being treated for coronary artery blockages," said Kuliopulos, Director of the Hemostasis and Thrombosis Lab at Tufts Medical Center.

Heart disease is the leading cause of death in the United States. The new approach could benefit patients who have had heart attacks or who need cardiac catheterization procedures to prop open clogged arteries with a stent. These patients face increased risk for blood clots that can cause heart attack and death. To reduce these risks, patients are currently treated with anti-clotting drugs, which increase their risk of life-threatening bleeding problems.

In a study to be published today in the journal Circulation, Tufts Medical Center researchers have discovered a mechanism to inhibit the ability of platelets to form clots without increasing the risk of bleeding. The new approach uses pepducins, which are able to travel inside cells to block receptors and inhibit molecular pathways that stimulate clot formation. By contrast, most approved drugs block receptors on the outside of cells. If successful, this new strategy could lead to an entirely new class of drugs.

The pepducin, PZ-128, inhibits PAR1, a platelet protein that stimulates clotting. When added to human blood samples, PZ-128 appears to inhibit clotting without affecting bleeding markers. It also clears out of the blood stream within hours, which should reduce the risk of long-term bleeding problems.

"Anytime you have a new molecule that exploits a novel mechanism of action, it's very exciting and the benefit to patients is potentially tremendous,'' said Carey Kimmelstiel, MD, Director of the Cardiac Catheterization Laboratory and Interventional Cardiology at Tufts Medical Center. "A new technology that can inhibit platelet function without increasing bleeding would be enormously powerful."

The next step is to evaluate the safety and effectiveness of the pepducin in humans. The five-year, $10 million NIH grant will fund the early stages of drug development. Researchers will first conduct a Phase I clinical trial in healthy human volunteers to determine whether the drug is safe. If successful, the grant will cover a multi-center Phase II clinical trial in 800 patients.

The research is the result of a long-term collaborative effort between laboratory scientists and the clinicians in the Cardiac Catheterization Laboratory at Tufts Medical Center.

"These exciting advances would not have been possible without this strong partnership," said Kuliopulos. "It is critical for researchers to have an understanding and appreciation of the clinical issues and practical matters concerning the real-world application of the drug."


'/>"/>

Contact: Julie Jette
jjette@tuftsmedicalcenter.org
617-636-3265
Tufts Medical Center
Source:Eurekalert

Related medicine news :

1. Lifespan/Tufts/Brown Center for AIDS Research renewed with $8.5 million NIH grant
2. Heuer M.D. Research Announces CardiaShred™ - First Medical Doctor Formulated, Heart Healthy Weight Loss, Energy and Lean Muscle Building Supplement
3. Podiatry Residents Advance Medical Training with New Online Resource
4. Electronic medical record improves physician compliance of reviewing portal images, study suggests
5. QuickMedical® Offers The WaveSense Blood Glucose Monitoring System
6. Corporate Whistle Blower Center Now Urges Medical Device Insiders To Be A Whistleblower If They Can Prove The Device Maker Knew Of A Failure & Said Nothing=Huge Rewards
7. Nurse Alert Senior Medical Alert System Announces Solution for Seniors to Help Reduce Medical Costs
8. DRE Medical Equipment Unveils FX-300+ Surgical Headlight and Light Source
9. Kernicterus Brain Damage in Babies Linked to Medical Malpractice
10. Medical Tourism: Uncharted Territory for Patients James Goldberg, Author of the American Medical Money Machine, Is Offering a New Consulting Service to Medical Patients Considering “Medical Tourism” Treatment
11. Unique program bringing electronic medical record data to ambulances lauded
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified personal trainer is helping ... fitness app. The fitness app plans to fix the two major problems leading the fitness ... size fits all type program , They don’t eliminate all the reasons people ...
(Date:6/25/2016)... Viejo, California (PRWEB) , ... June 25, 2016 , ... ... to fit their specific project," said Christina Austin - CEO of Pixel Film Studios. ... fully customizable and all within Final Cut Pro X . Simply select a ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the ... In terms of the latter, setting the bar too high can result in disappointment, ... just slow progress toward their goal. , Research from PsychTests.com reveals ...
(Date:6/24/2016)... Dallas, Texas (PRWEB) , ... June 24, 2016 ... ... 12th International Conference and Scientific Sessions in Dallas that it will receive two ... Announcement of the grants came as PHA marked its 25th anniversary by recognizing ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are ... Code Talker Award, an essay contest in which patients and their families pay tribute ... presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Tenn. , June 24, 2016  Arkis ... providing less invasive and more durable cerebrospinal fluid ... in funding.  The Series-A funding is led by ... Lighthouse Fund, and other private investors.  Arkis, new ... neurosurgical instrumentation and the market release of its ...
(Date:6/23/2016)... , June 23, 2016 ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, ... Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast to ... The global pharmaceutical excipients market ... at a CAGR of 6.1% in the forecast period ...
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on the ... announced that patient enrollment in its ongoing randomized ... has exceeded 50% of its 24-patient target. Capricor ... the third quarter of 2016, and to report ...
Breaking Medicine Technology: